NuSil completes work on silicone facility

By Staff Reporter

- Last updated on GMT

US firm NuSil Technology says new clean room manufacturing plant will help meet growing demand for silicone compounds for delivery systems.

Silicones, not to be confused with the element silicone, are polymer excipients with which active pharmaceutical ingredients (API) are combined, or compounded, enabling improved drug delivery.+

Nusil’s new 2,400 sqft facility, which is near the firm’s headquarters in California, will provide contract manufacturing and silicone compounding services for pharma and biotech industry clients.

Brian Reilly, NuSil’s product director for health care materials, explained that: “We’ve seen an increase in demand from manufacturers of controlled release and combination products to compound and deliver silicones that contain APIs.

As a direct result of that spike in interest, we felt it was time to make a capital investment in multiple facility expansions that would ensure all future compounding was done in a safe and controlled environment.”

Transdermal delivery

The completion of the new facility follows just days after NuSil expanded its range of drug delivery silicones (DDS) with two new transdermal adhesives.

The first new silicone, DDR-1370, is a pressure sensitive adhesive (PSA) designed to provide both “high cohesive strength and high release force,” which NuSil claim gives the material “favourable temporary adhesive properties.”

DDR-4355, in contrast, is a transparent, soft silicone gel that has a high-surface-tack, temporary silicone adhesive.

Speaking when the products launched on April 8, Reilly said that: “With a PSA and a tacky gel available to the transdermal drug delivery market, we are striving to offer two great options for temporary adhesives.

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...